CSE Interview with Rob Abenante CEO of Abattis Bioceuticals Corp.

0

Share

Other News

Abattis Provides Comprehensive Update June 17, 2020
Abattis Provides Update on Trading Halt and Corporate Developments November 8, 2019
Abattis Announces Successful Closing of Pro Natura Acquisition May 21, 2019
Abattis Announces Acquisition of European Nutraceutical Company and Provides Corporate Updates April 3, 2019
Abattis Provides Update on Trading Halt and Announces Management Conference Call February 19, 2019

Abattis Bioceuticals is a life sciences company that aggregates, integrates, and invests in biotechnology services internationally.

Exchange Listings
CSE: ATT | OTC: ATTBF

Subscribe To Our News List
Sign up to receive alerts on Abattis news releases and product announcements

Email:

Abattis Bioceuticals Corporation

T: 1-604-681-1269

Follow @abattis

Disclaimer
Privacy Policy
Terms and Conditions
Return Policy